RESUMEN
Change history: In this Letter, the rotation signs around 90°, 135° and 15° were missing and in the HTML, Extended Data Tables 2 and 3 were the wrong tables; these errors have been corrected online.
RESUMEN
The human MT1 and MT2 melatonin receptors1,2 are G-protein-coupled receptors (GPCRs) that help to regulate circadian rhythm and sleep patterns3. Drug development efforts have targeted both receptors for the treatment of insomnia, circadian rhythm and mood disorders, and cancer3, and MT2 has also been implicated in type 2 diabetes4,5. Here we report X-ray free electron laser (XFEL) structures of the human MT2 receptor in complex with the agonists 2-phenylmelatonin (2-PMT) and ramelteon6 at resolutions of 2.8 Å and 3.3 Å, respectively, along with two structures of function-related mutants: H2085.46A (superscripts represent the Ballesteros-Weinstein residue numbering nomenclature7) and N862.50D, obtained in complex with 2-PMT. Comparison of the structures of MT2 with a published structure8 of MT1 reveals that, despite conservation of the orthosteric ligand-binding site residues, there are notable conformational variations as well as differences in [3H]melatonin dissociation kinetics that provide insights into the selectivity between melatonin receptor subtypes. A membrane-buried lateral ligand entry channel is observed in both MT1 and MT2, but in addition the MT2 structures reveal a narrow opening towards the solvent in the extracellular part of the receptor. We provide functional and kinetic data that support a prominent role for intramembrane ligand entry in both receptors, and suggest that there might also be an extracellular entry path in MT2. Our findings contribute to a molecular understanding of melatonin receptor subtype selectivity and ligand access modes, which are essential for the design of highly selective melatonin tool compounds and therapeutic agents.
Asunto(s)
Electrones , Rayos Láser , Modelos Moleculares , Receptor de Melatonina MT2/química , Receptor de Melatonina MT2/metabolismo , Cristalización , Diabetes Mellitus Tipo 2/genética , Humanos , Indenos/química , Indenos/metabolismo , Ligandos , Melatonina/análogos & derivados , Melatonina/química , Melatonina/metabolismo , Simulación del Acoplamiento Molecular , Simulación de Dinámica Molecular , Mutación , Receptor de Melatonina MT1/química , Receptor de Melatonina MT1/metabolismo , Receptor de Melatonina MT2/genética , Relación Estructura-Actividad , Especificidad por SustratoRESUMEN
Melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone that maintains circadian rhythms1 by synchronization to environmental cues and is involved in diverse physiological processes2 such as the regulation of blood pressure and core body temperature, oncogenesis, and immune function3. Melatonin is formed in the pineal gland in a light-regulated manner4 by enzymatic conversion from 5-hydroxytryptamine (5-HT or serotonin), and modulates sleep and wakefulness5 by activating two high-affinity G-protein-coupled receptors, type 1A (MT1) and type 1B (MT2)3,6. Shift work, travel, and ubiquitous artificial lighting can disrupt natural circadian rhythms; as a result, sleep disorders affect a substantial population in modern society and pose a considerable economic burden7. Over-the-counter melatonin is widely used to alleviate jet lag and as a safer alternative to benzodiazepines and other sleeping aids8,9, and is one of the most popular supplements in the United States10. Here, we present high-resolution room-temperature X-ray free electron laser (XFEL) structures of MT1 in complex with four agonists: the insomnia drug ramelteon11, two melatonin analogues, and the mixed melatonin-serotonin antidepressant agomelatine12,13. The structure of MT2 is described in an accompanying paper14. Although the MT1 and 5-HT receptors have similar endogenous ligands, and agomelatine acts on both receptors, the receptors differ markedly in the structure and composition of their ligand pockets; in MT1, access to the ligand pocket is tightly sealed from solvent by extracellular loop 2, leaving only a narrow channel between transmembrane helices IV and V that connects it to the lipid bilayer. The binding site is extremely compact, and ligands interact with MT1 mainly by strong aromatic stacking with Phe179 and auxiliary hydrogen bonds with Asn162 and Gln181. Our structures provide an unexpected example of atypical ligand entry for a non-lipid receptor, lay the molecular foundation of ligand recognition by melatonin receptors, and will facilitate the design of future tool compounds and therapeutic agents, while their comparison to 5-HT receptors yields insights into the evolution and polypharmacology of G-protein-coupled receptors.
Asunto(s)
Electrones , Rayos Láser , Modelos Moleculares , Receptor de Melatonina MT1/química , Receptor de Melatonina MT1/metabolismo , Acetamidas/química , Acetamidas/metabolismo , Secuencia de Aminoácidos , Antidepresivos/química , Antidepresivos/metabolismo , Cristalización , Humanos , Indenos/química , Indenos/metabolismo , Ligandos , Melatonina/análogos & derivados , Melatonina/química , Simulación del Acoplamiento Molecular , Mutación , Receptor de Melatonina MT1/agonistas , Receptor de Melatonina MT1/genética , Receptor de Serotonina 5-HT2C/química , Relación Estructura-Actividad , Especificidad por SustratoRESUMEN
Melatonin is a small natural compound, so called a neuro-hormone that is synthesized mainly in pineal gland in animals. Its main role is to master the clock of the body, under the surveillance of light. In other words, it transfers the information concerning night and day to the peripheral organs which, without it, could not "know" which part of the circadian rhythm the body is in. Besides its main circadian and circannual rhythms mastering, melatonin is reported to be a radical scavenger and/or an antioxidant. Because radical scavengers are chemical species able to neutralize highly reactive and toxic species such as reactive oxygen species, one would like to transfer this property to living system, despite impossibilities already largely reported in the literature. In the present commentary, we refresh the memory of the readers with this notion of radical scavenger, and review the possible evidence that melatonin could be an in vivo radical scavenger, while we only marginally discuss here the fact that melatonin is a molecular antioxidant, a feature that merits a review on its own. We conclude four things: (i) the evidence that melatonin is a scavenger in acellular systems is overwhelming and could not be doubted; (ii) the transposition of this property in living (animal) systems is (a) theoretically impossible and (b) not proven in any system reported in the literature where most of the time, the delay of the action of melatonin is over several hours, thus signing a probable induction of cellular enzymatic antioxidant defenses; (iii) this last fact needs a confirmation through the discovery of a nuclear factor-a key relay in induction processes-that binds melatonin and is activated by it and (iv) we also gather the very important description of the radical scavenging capacity of melatonin in acellular systems that is now proven and shared by many other double bond-bearing molecules. We finally discussed briefly on the reason-scientific or else-that led this description, and the consequences of this claim, in research, in physiology, in pathology, but most disturbingly in therapeutics where a vast amount of money, hope, and patient bien-être are at stake.
Asunto(s)
Melatonina , Glándula Pineal , Animales , Humanos , Melatonina/metabolismo , Antioxidantes/farmacología , Antioxidantes/metabolismo , Glándula Pineal/metabolismo , Ritmo Circadiano/fisiología , Especies Reactivas de Oxígeno/metabolismoRESUMEN
The adenosine A2A receptor (A2AR) has been identified as a therapeutic target for treating neurodegenerative diseases and cancer. In recent years, we have highlighted the 2-aminoquinazoline heterocycle as an promising scaffold for designing new A2AR antagonists, exemplified by 6-bromo-4-(furan-2-yl)quinazolin-2-amine 1 (Ki (hA2AR) = 20 nM). Here, we report the synthesis of new 2-aminoquinazoline derivatives with substitutions at the C6- and C7-positions, and the introduction of aminoalkyl chains containing tertiary amines at the C2-position to enhance antagonist activity and solubility properties. Compound 5m showed a high affinity for hA2AR with a Ki value of 5 nM and demonstrated antagonist activity with an IC50 of 6 µM in a cyclic AMP assay. Introducing aminopentylpiperidine and 4-[(piperidin-1-yl)methyl]aniline substituents maintained the binding affinities (9x, Ki = 21 nM; 10d, Ki = 15 nM) and functional antagonist activities (9x, IC50 = 9 µM; 10d, IC50 = 5 µM) of the synthesized compounds while improving solubility. This study provides insights into the future development of A2AR antagonists for therapeutic applications.
Asunto(s)
Antagonistas del Receptor de Adenosina A2 , Quinazolinas , Receptor de Adenosina A2A , Quinazolinas/química , Quinazolinas/farmacología , Quinazolinas/síntesis química , Antagonistas del Receptor de Adenosina A2/química , Antagonistas del Receptor de Adenosina A2/síntesis química , Antagonistas del Receptor de Adenosina A2/farmacología , Receptor de Adenosina A2A/metabolismo , Receptor de Adenosina A2A/química , Humanos , Relación Estructura-Actividad , Estructura Molecular , AMP Cíclico/metabolismo , Solubilidad , Unión ProteicaRESUMEN
In mammals, MT1 and MT2 melatonin receptors are high affinity G protein-coupled receptors and are thought to be involved in the integration of the melatonin signaling throughout the brain and periphery. In the present study, we describe a new melatonin binding site, named MTx, with a peculiar pharmacological profile. This site had a low affinity for 2-[125I]-melatonin in saturation assays in hypothalamus and retina (pKD = 9.13 {plus minus} 0.05, Bmax = 1.12 {plus minus} 0.11 fmol/mg protein and pKD = 8.81 {plus minus} 0.50, Bmax = 7.65 {plus minus} 2.64 fmol/mg protein, respectively) and a very high affinity, in competition assays, for melatonin (pKi = 13.08 {plus minus} 0.18), and other endogenous compounds. Using autoradiography, we showed a preferential localization of the MTx in periventricular areas of the sheep brain, with a density 3 to 8 times higher than those observed for ovine MT1 In addition, using a set of well-characterized ligands, we showed that this site did not correspond to any of the following receptors: MT1, MT2, MT3 , D1, D2, noradrenergic, nor 5-HT2 Based on its affinity for melatonin, MTx did not seem to be implicated in the integration of cerebral melatonin concentration variations since they were saturating for MTx. Nevertheless, it remained of prime importance because of its periventricular distribution, in close contact with the CSF, and its peculiar pharmacological profile responding to both melatoninergic and serotoninergic compounds. Significance Statement Herein a putative new melatonin binding site is described in sheep brain parts in close contact with the 3rd ventricle. The characteristics of the pharmacological profile of this site is different from anything previously reported in the literature. The present work forms the basis of future full pharmacological characterization.
RESUMEN
Using histamine as lead molecule, a library of (hetero)aryl substituted thiazol-2,4-yl derivatives incorporating pyridine as proton shuttling moiety were obtained and investigated as activators of human carbonic anhydrase (CA, EC 4.2.1.1) isoforms I, II, VII and XIV. Some derivatives displayed good activating and selectivity profiles. This study provides an interesting opportunity to study the thiazole scaffold for the design of CA activators (CAAs), possibly acting on the central nervous system and targeting pathologies involving memory and learning impairments.
Asunto(s)
Anhidrasa Carbónica II/metabolismo , Anhidrasa Carbónica I/metabolismo , Anhidrasas Carbónicas/metabolismo , Activadores de Enzimas/farmacología , Tiazoles/farmacología , Activadores de Enzimas/química , Humanos , Estructura Molecular , Tiazoles/químicaRESUMEN
For over half a century, the carbazole skeleton has been the key structural motif of many biologically active compounds including natural and synthetic products. Carbazoles have taken an important part in all the existing anti-cancer drugs because of their discovery from a large variety of organisms, including bacteria, fungi, plants, and animals. In this article, we specifically explored the literature from 2012 to 2018 on the anti-tumour activities reported to carbazole derivatives and we have critically collected the most significant data. The most described carbazole anti-tumour agents were classified according to their structure, starting from the tricyclic-carbazole motif to fused tetra-, penta-, hexa- and heptacyclic carbazoles. To date, three derivatives are available on the market and approved in cancer therapy.
Asunto(s)
Antineoplásicos/síntesis química , Antineoplásicos/farmacología , Carbazoles/química , Carbazoles/farmacología , Neoplasias/tratamiento farmacológico , Animales , Antineoplásicos/química , Proliferación Celular/efectos de los fármacos , Humanos , Estructura Molecular , Neoplasias/patologíaRESUMEN
Imidazo[1,2a]pyridines have gained much interest in the field of medicinal chemistry research. In the aim of accessing new privileged structure, we decided to design and synthesize 8-aminated-imidazo[1,2a]pyridines substituted on positions 2 and 6. This scaffold, rarely found in the literature, was obtained via palladium-catalyzed coupling reactions (Suzuki reaction or N-hydroxysuccinimidyl activated ester method) and tested on adenosine receptor A2A. We demonstrated how incorporation of an exocyclic amine enhanced affinity towards this receptor while maintaining low cytotoxicity.
Asunto(s)
Diseño de Fármacos , Piridinas/química , Antagonistas del Receptor de Adenosina A2/síntesis química , Antagonistas del Receptor de Adenosina A2/metabolismo , Antagonistas del Receptor de Adenosina A2/farmacología , Sitios de Unión , Catálisis , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Células HEK293 , Humanos , Simulación del Acoplamiento Molecular , Paladio/química , Estructura Terciaria de Proteína , Piridinas/metabolismo , Piridinas/farmacología , Receptor de Adenosina A2A/química , Receptor de Adenosina A2A/metabolismo , Relación Estructura-ActividadRESUMEN
The chloroquinoline scaffold is characteristic of anti-malarial drugs such as chloroquine (CQ) or amodiaquine (AQ). These drugs are also described for their potential effectiveness against prion disease, HCV, EBV, Ebola virus, cancer, Parkinson or Alzheimer diseases. Amyloid precursor protein (APP) metabolism is deregulated in Alzheimer's disease. Indeed, CQ modifies amyloid precursor protein (APP) metabolism by precluding the release of amyloid-beta peptides (Aß), which accumulate in the brain of Alzheimer patients to form the so-called amyloid plaques. We showed that AQ and analogs have similar effects although having a higher cytotoxicity. Herein, two new series of compounds were synthesized by replacing 7-chloroquinolin-4-amine moiety of AQ by 2-aminomethylaniline and 2-aminomethylphenyle moieties. Their structure activity relationship was based on their ability to modulate APP metabolism, Aß release, and their cytotoxicity similarly to CQ. Two compounds 15a, 16a showed interesting and potent effect on the redirection of APP metabolism toward a decrease of Aß peptide release (in the same range compared to AQ), and a 3-10-fold increased stability of APP carboxy terminal fragments (CTFα and AICD) without obvious cellular toxicity at 100⯵M.
Asunto(s)
Precursor de Proteína beta-Amiloide/metabolismo , Compuestos de Anilina/metabolismo , Enfermedad de Alzheimer/metabolismo , Enfermedad de Alzheimer/patología , Amodiaquina/química , Amodiaquina/metabolismo , Péptidos beta-Amiloides/química , Péptidos beta-Amiloides/metabolismo , Precursor de Proteína beta-Amiloide/antagonistas & inhibidores , Compuestos de Anilina/química , Compuestos de Anilina/farmacología , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Cloroquina/química , Cloroquina/metabolismo , Humanos , Unión Proteica , Relación Estructura-ActividadRESUMEN
The development of adenosine A2A receptor antagonists has received much interest in recent years for the treatment of neurodegenerative diseases. Based on docking studies, a new series of 2-arylbenzoxazoles has been identified as potential A2AR antagonists. Structure-affinity relationship was investigated in position 2, 5 and 6 of the benzoxazole heterocycle leading to compounds with a micromolar affinity towards the A2A receptor. Compound F1, with an affinity of 1 µm, presented good absorption, distribution, metabolism and excretion properties with an excellent aqueous solubility (184 µm) without being cytotoxic at 100 µm. This compound, along with low-molecular weight compound D1 (Ki = 10 µm), can be easily modulated and thus considered as relevant starting points for further hit-to-lead optimisation.
Asunto(s)
Antagonistas del Receptor de Adenosina A2/farmacología , Benzoxazoles/farmacología , Diseño de Fármacos , Receptor de Adenosina A2A/metabolismo , Antagonistas del Receptor de Adenosina A2/síntesis química , Antagonistas del Receptor de Adenosina A2/química , Benzoxazoles/síntesis química , Benzoxazoles/química , Muerte Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Células HEK293 , Humanos , Modelos Moleculares , Estructura Molecular , Solubilidad , Relación Estructura-Actividad , Células Tumorales CultivadasRESUMEN
This work reports a high-performance liquid chromatography normal-phase methodology to elucidate enantiomers of naphthalene derivatives, evaluated as melatoninergic agonists. For this purpose four different polysaccharide based chiral stationary phases were evaluated, namely Chiralcel OD-H (cellulose tris-3,5-dimethylphenylcarbamate), Chiralcel OJ (cellulose tris-methylbenzoate), Chiralpak AD (amylose tris-3,5-dimethylphenylcarbamate) and Chiralpak AS (amylose tris-(S)-1-phenylethylcarbamate) with different alcoholic modifiers on different amounts in n-heptane. A temperature study was carried out, between 20 and 40 °C and the apparent thermodynamic parameters were calculated thanks to the Van't Hoff linearization. For all compounds (except 3), ΔΔH° and ΔΔS° exhibited positive values ranging from 791.2 to 9999.3 J/mol and from 3.9 to 37.8 J/K/mol respectively, indicating entropically driven separations. Optimized conditions led to goof resolution of 2.37 for compound 1 on Chiralpak AS, with heptane-2-propanol 90:10 (v/v), at a temperature of 30 °C. Then they were transposed to the preparative scale for compound 1, generating 22 mg of each enantiomer with an 80% yield. The limits of detection and of quantification were determined to allow the calculation of the enantiomeric excess. They were found with very low values, equal to 0.32 and 1.05 µ m and 0.33 and 1.11 µ m, respectively, for peaks 1 and 2 of compound 1.
Asunto(s)
Amilosa/análogos & derivados , Cromatografía Líquida de Alta Presión/métodos , Melatonina/química , Naftalenos/química , Amilosa/química , Cromatografía Líquida de Alta Presión/instrumentación , Melatonina/agonistas , Estructura Molecular , Naftalenos/agonistas , Estereoisomerismo , Temperatura , TermodinámicaRESUMEN
Performing CD-EKC, baseline separation of five agomelatine analogs, potential antidepressant compounds, was achieved. A method for the enantioresolution and determination of enantiomeric purity of these naphthalene derivatives was developed using capillaries dynamically coated with polyethylene oxide and anionic cyclodextrins (highly sulfated CD) as chiral selectors. Operational parameters such as the nature and concentration of the cyclodextrins were investigated. In a second step the implementation of a dual cyclodextrin system was found to strongly enhance the LOD of the analytes. After optimization, best conditions were a 25 mM phosphate buffer at pH 2.5 containing 5% w/v (i.e. 19.7 mM) of highly sulfated-γ-CD and 10 mM of 6-monodeoxy-6-monoamino-ß-CD dual system, leading to resolution of, at least, 3.6 in 35 min. A preliminary validation of the developed method was undertaken: linearity, precision, and LOD and LOQ were evaluated. The latest ones were found equal to 0.25 and 0.82 µM and to 0.31 and 0.96 µM respectively for the first and the second enantiomer of compound 1.
Asunto(s)
Acetamidas/análisis , Acetamidas/química , Cromatografía Capilar Electrocinética Micelar/instrumentación , Cromatografía Capilar Electrocinética Micelar/métodos , Ciclodextrinas/química , Acetamidas/aislamiento & purificación , Análisis de los Mínimos Cuadrados , Límite de Detección , Reproducibilidad de los Resultados , EstereoisomerismoRESUMEN
Herein we describe the synthesis of novel tricyclic analogues issued from the rigidification of the methoxy group of the benzofuranic analogue of melatonin as MT1 and MT2 ligands. Most of the synthesized compounds displayed high binding affinities at MT1 and MT2 receptors subtypes. Compound 6b (MT1, Ki=0.07nM; MT2, Ki=0.08nM) exhibited with the vinyl 6c and allyl 6d the most interesting derivatives of this series. Functional activity of these compounds showed full agonist activity with EC50 in the nanomolar range. Compounds 6a (EC50=0.8nM and Emax=98%) and 6b (EC50=0.2nM and Emax=121%) exhibited good pharmacological profiles.
Asunto(s)
Benzofuranos/química , Melatonina/análogos & derivados , Amidas/química , Animales , Benzofuranos/síntesis química , Benzofuranos/metabolismo , Células CHO/efectos de los fármacos , Técnicas de Química Sintética , Cricetulus , Células HEK293/efectos de los fármacos , Humanos , Ligandos , Melatonina/agonistas , Melatonina/metabolismo , Receptor de Melatonina MT1/metabolismo , Receptor de Melatonina MT2/metabolismo , Relación Estructura-ActividadRESUMEN
Melatonin receptors have been studied for several decades. The low expression of the receptors in tissues led the scientific community to find a substitute for the natural hormone melatonin, the agonist 2-[125I]-iodomelatonin. Using the agonist, several hundreds of studies were conducted, including the discovery of agonists and antagonists for the receptors and minute details about their molecular behavior. Recently, we attempted to expand the panel of radioligands available for studying the melatonin receptors by using the newly discovered compounds SD6, DIV880, and S70254. These compounds were characterized for their affinities to the hMT1 and hMT2 recombinant receptors and their functionality in the classical GTPï§S system. SD6 is a full agonist, equilibrated between the receptor isoforms, whereas S70254 and DIV880 are only partial MT2 agonists, with Ki in the low nanomolar range while they have no affinity to MT1 receptors. These new tools will hopefully allow for additions to the current body of information on the native localization of the receptor isoforms in tissues.
Asunto(s)
Radiofármacos/metabolismo , Receptor de Melatonina MT1/metabolismo , Receptor de Melatonina MT2/metabolismo , Animales , Células CHO , Cricetinae , Cricetulus , Humanos , Cinética , Ligandos , Melatonina/análogos & derivados , Melatonina/metabolismo , Radiofármacos/química , Proteínas Recombinantes/metabolismo , Análisis de RegresiónRESUMEN
Novel conformationally restricted analogues of agomelatine were synthesized and pharmacologically evaluated at MT1 and MT2 melatoninergic receptors. Replacement of the N-acetyl side chain of agomelatine by oxathiadiazole-2-oxide (compound 3), oxadiazole-5(4H)-one (compound 4), tetrazole (compound 5), oxazolidinone (compound 7a), pyrrolidinone (compound 7b), imidazolidinedione (compound 12), thiazole (compounds 13 and 14) and isoxazole moieties (compound 15) led to a decrease of the melatoninergic binding affinities, particularly at MT1. Compounds 7a and 7b exhibiting nanomolar affinity towards the MT2 receptors subtypes have shown the most interesting pharmacological results of this series with the appearance of a weak MT2-selectivity.
Asunto(s)
Acetamidas/química , Receptor de Melatonina MT1/metabolismo , Receptor de Melatonina MT2/metabolismo , Animales , Células CHO , Cricetinae , Isoxazoles/metabolismo , Ligandos , Oxazolidinonas/metabolismo , Pirrolidinonas/metabolismo , Ensayo de Unión Radioligante , Relación Estructura-Actividad , Tetrazoles/metabolismo , Tiazoles/metabolismoRESUMEN
Melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone that possesses a wide range of biological effects. Most of the main recognized effects of this hormone in mammals are due to its interaction with two G protein-coupled receptors, MT1 and MT2. Ligand-binding studies have been based on the use of its radioligand analog, 2[125I]-iodomelatonin, a super agonist discovered in the early 1990s. This compound has been used in most of the binding studies reported in the literature. Nevertheless, more recently other possibilities arose. This chapter is a brief summary of those alternative radioligands and of their benefits one can find in using them.
Asunto(s)
Radioisótopos de Yodo , Melatonina , 5-Metoxitriptamina , Animales , Ligandos , Mamíferos/metabolismo , Melatonina/farmacología , Receptores de MelatoninaRESUMEN
In our constant search for new successors of agomelatine, we report herein a new series of compounds resulting from bioisosteric modulation of the naphthalene ring. The isoquinoline and tetrahydroisoquinoline derivatives were synthesized and pharmacologically evaluated. This isosteric replacement of the naphthalene group of agomelatine has led to potent agonist and partial agonist compounds with nanomolar melatonergic binding affinities. Overall, the presence of a nitrogen atom was accompanied with a decrease in the binding affinity toward both MT1 and MT2 and the loss of 5HT2C response, especially for tetrahydroisoquinoline in comparison with the parent compound. Interestingly, due to the presence of this nitrogen atom, a notable improvement in the pharmacokinetic properties was observed for all compounds.
Asunto(s)
Isoquinolinas/farmacología , Receptores de Melatonina/agonistas , Animales , Células Cultivadas , Cricetulus , Relación Dosis-Respuesta a Droga , Humanos , Isoquinolinas/química , Isoquinolinas/metabolismo , Ligandos , Simulación del Acoplamiento Molecular , Estructura Molecular , Relación Estructura-ActividadRESUMEN
The past fifty years have been marked by the surge of neurodegenerative diseases. Unfortunately, current treatments are only symptomatic. Hence, the search for new and innovative therapeutic targets for curative treatments becomes a major challenge. Among these targets, the adenosine A2A receptor (A2AAR) has been the subject of much research in recent years. In this paper, we report the design, synthesis and pharmacological analysis of quinazoline derivatives as A2AAR antagonists with high ligand efficiency. This class of molecules has been discovered by a virtual screening and bears no structural semblance with reference antagonist ZM-241385. More precisely, we identified a series of 2-aminoquinazoline as promising A2AAR antagonists. Among them, one compound showed a high affinity towards A2AAR (21a, Ki = 20 nM). We crystallized this ligand in complex with A2AAR, confirming one of our predicted docking poses and opening up possibilities for further optimization to derive selective ligands for specific adenosine receptor subtypes.
Asunto(s)
Antagonistas del Receptor de Adenosina A2 , Antagonistas de Receptores Purinérgicos P1 , Antagonistas del Receptor de Adenosina A2/química , Antagonistas del Receptor de Adenosina A2/farmacología , Ligandos , Simulación del Acoplamiento Molecular , Antagonistas de Receptores Purinérgicos P1/farmacología , Quinazolinas/farmacología , Receptor de Adenosina A2A/química , Relación Estructura-ActividadRESUMEN
Melatonin is a neurohormone that modulates several physiological functions in mammals through the activation of melatonin receptor type 1 and 2 (MT1 and MT2). The melatonergic system is an emerging therapeutic target for new pharmacological interventions in the treatment of sleep and mood disorders; thus, imaging tools to further investigate its role in the brain are highly sought-after. We aimed to develop selective radiotracers for in vivo imaging of both MT1 and MT2 by positron emission tomography (PET). We identified four previously reported MT ligands with picomolar affinities to the target based on different scaffolds which were also amenable for radiolabeling with either carbon-11 or fluorine-18. [11C]UCM765, [11C]UCM1014, [18F]3-fluoroagomelatine ([18F]3FAGM), and [18F]fluoroacetamidoagomelatine ([18F]FAAGM) have been synthesized in high radiochemical purity and evaluated in wild-type rats. All four tracers showed moderate to high brain permeability in rats with maximum standardized uptake values (SUVmax of 2.53, 1.75, 3.25, and 4.47, respectively) achieved 1-2 min after tracer administration, followed by a rapid washout from the brain. Several melatonin ligands failed to block the binding of any of the PET tracer candidates, while in some cases, homologous blocking surprisingly resulted in increased brain retention. Two 18F-labeled agomelatine derivatives were brought forward to PET scans in non-human primates and autoradiography on human brain tissues. No specific binding has been detected in blocking studies. To further investigate pharmacokinetic properties of the putative tracers, microsomal stability, plasma protein binding, log D, and membrane bidirectional permeability assays have been conducted. Based on the results, we conclude that the fast first pass metabolism by the enzymes in liver microsomes is the likely reason of the failure of our PET tracer candidates. Nevertheless, we showed that PET imaging can serve as a valuable tool to investigate the brain permeability of new therapeutic compounds targeting the melatonergic system.